Cytek Biosciences (CTKB) Stock Price, News & Analysis $7.72 +0.06 (+0.78%) (As of 02:15 PM ET) Add Compare Share Share Today's Range$7.47▼$7.7550-Day Range$4.10▼$7.6652-Week Range$3.80▼$13.77Volume331,600 shsAverage Volume1.01 million shsMarket Capitalization$1.05 billionP/E RatioN/ADividend YieldN/APrice Target$10.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Cytek Biosciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside34.9% Upside$10.33 Price TargetShort InterestBearish7.21% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$593,800 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.12) to ($0.07) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.67 out of 5 starsMedical Sector779th out of 943 stocksMedical Devices Industry4th out of 6 stocks 3.3 Analyst's Opinion Consensus RatingCytek Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.33, Cytek Biosciences has a forecasted upside of 34.9% from its current price of $7.66.Amount of Analyst CoverageCytek Biosciences has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.21% of the float of Cytek Biosciences has been sold short.Short Interest Ratio / Days to CoverCytek Biosciences has a short interest ratio ("days to cover") of 7.8.Change versus previous monthShort interest in Cytek Biosciences has recently increased by 5.81%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCytek Biosciences does not currently pay a dividend.Dividend GrowthCytek Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CTKB. Previous Next 0.6 News and Social Media Coverage Search InterestOnly 3 people have searched for CTKB on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows2 people have added Cytek Biosciences to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cytek Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $593,800.00 in company stock.Percentage Held by Insiders15.90% of the stock of Cytek Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions56.50% of the stock of Cytek Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cytek Biosciences are expected to grow in the coming year, from ($0.12) to ($0.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cytek Biosciences is -76.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cytek Biosciences is -76.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCytek Biosciences has a P/B Ratio of 2.42. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Cytek Biosciences Stock (NASDAQ:CTKB)Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis. The company also provides reagents and kits, including cFluor reagents, which are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, which are automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific region; and through distributors or sales agents in European, Latin American, the Middle Eastern, and the Asia-Pacific countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.Read More CTKB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CTKB Stock News HeadlinesNovember 22, 2023 | finance.yahoo.comInsider Sell Alert: CTO Ming Yan Sells 20,000 Shares of Cytek Biosciences Inc (CTKB)November 16, 2023 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Cytek Biosciences (CTKB), DENTSPLY SIRONA (XRAY)December 11, 2023 | Edge On The Street (Ad)Is This The Most Overlooked Gold Investment Strategy of 2024?There is little debate on the potential of gold in the next year and decade. The real issue becomes - what's the best gold investment strategy today? Some investors are opting for a unique "royalty" alternative that outshines other options like holding gold bullion or investing in volatile mining stocks.November 14, 2023 | finance.yahoo.comCytek Biosciences to participate in the Piper Sandler 35th Annual Healthcare ConferenceNovember 12, 2023 | finance.yahoo.comCytek Biosciences, Inc. (NASDAQ:CTKB) Q3 2023 Earnings Call TranscriptNovember 9, 2023 | finance.yahoo.comCytek Biosciences Inc (CTKB) Q3 2023 Earnings Report SummaryNovember 8, 2023 | finance.yahoo.comCytek® Aurora™ CS System Wins BioTech Breakthrough Award for ‘Cell Sorting Product of the Year’November 7, 2023 | msn.comCytek Biosciences GAAP EPS of -$0.05 misses by $0.08, revenue of $48M misses by $7.48MDecember 11, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.November 7, 2023 | finance.yahoo.comCytek Biosciences Reports Third Quarter 2023 Financial ResultsOctober 31, 2023 | finance.yahoo.comEarnings Preview: Cytek Biosciences, Inc. (CTKB) Q3 Earnings Expected to DeclineOctober 24, 2023 | markets.businessinsider.comMorgan Stanley Maintains Equal-Weight Rating for Cytek Biosciences: Here's What You Need To KnowOctober 19, 2023 | finance.yahoo.comCytek Biosciences to Report Third Quarter 2023 Financial Results on November 7, 2023October 12, 2023 | finance.yahoo.comInsider Sell: Cytek Biosciences Inc President and CEO Wenbin Jiang Sells 20,000 SharesSeptember 27, 2023 | finance.yahoo.comCytek® Biosciences Achieves ISO 13485 Certification at HeadquartersSeptember 21, 2023 | benzinga.comMassive Insider Trade At Cytek BiosciencesSeptember 21, 2023 | finance.yahoo.comInsider Sell: CTO Ming Yan Sells 20,000 Shares of Cytek Biosciences IncSeptember 20, 2023 | finance.yahoo.comCytek Biosciences to Participate in the 2023 Cantor Fitzgerald Global Healthcare ConferenceSeptember 20, 2023 | finance.yahoo.comCytek® Biosciences Cell Analysis Solutions Take Center Stage at Upcoming Clinical Conferences in the US and EuropeSeptember 9, 2023 | finance.yahoo.comInsider Sell: Cytek Biosciences Inc CEO Wenbin Jiang Sells 20,000 SharesSeptember 6, 2023 | finance.yahoo.comCytek Biosciences to participate in the Morgan Stanley 21st Annual Global Healthcare ConferenceSeptember 4, 2023 | finance.yahoo.comWith 56% institutional ownership, Cytek Biosciences, Inc. (NASDAQ:CTKB) is a favorite amongst the big gunsAugust 28, 2023 | finance.yahoo.comCytek Biosciences Appoints Dr. Philippe Busque Senior Vice President of Global Sales & ServicesAugust 10, 2023 | finance.yahoo.comCytek Biosciences to Participate in the UBS MedTech, Tools and Genomics SummitAugust 9, 2023 | finance.yahoo.comCytek Biosciences, Inc. (CTKB) Q2 Earnings Lag EstimatesAugust 8, 2023 | finance.yahoo.comCytek Biosciences Reports Second Quarter 2023 Financial ResultsAugust 8, 2023 | markets.businessinsider.comWhat Wall Street expects from Cytek Biosciences,'s earningsSee More Headlines Receive CTKB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cytek Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/07/2023Today12/11/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/27/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Medical Devices Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CTKB CUSIPN/A CIK1831915 Webwww.cytekdev.com Phone877-922-9835FaxN/AEmployees688Year FoundedN/APrice Target and Rating Average Stock Price Target$10.33 High Stock Price Target$14.00 Low Stock Price Target$7.00 Potential Upside/Downside+34.9%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$2.58 million Net Margins-7.61% Pretax Margin-8.58% Return on Equity-1.73% Return on Assets-1.40% Debt Debt-to-Equity RatioN/A Current Ratio7.20 Quick Ratio6.06 Sales & Book Value Annual Sales$183.12 million Price / Sales5.67 Cash Flow$0.07 per share Price / Cash Flow105.38 Book Value$3.16 per share Price / Book2.42Miscellaneous Outstanding Shares135,549,000Free Float113,997,000Market Cap$1.04 billion OptionableNot Optionable Beta1.32 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Wenbin Jiang Ph.D. (Age 59)President, CEO & Chairman of the Board Comp: $964.21kDr. Ming Yan Ph.D. (Age 60)CTO & Director Comp: $616.26kMs. Valerie T. Barnett J.D. (Age 48)General Counsel & Corporate Secretary Comp: $535.98kMr. Patrik Sebastian Jeanmonod (Age 57)Chief Financial Officer Comp: $412.54kMr. Chris Williams (Age 54)Chief Operating Officer Mr. Paul D. GoodsonHead of Investor RelationsDr. Allen B. Poirson Ph.D. (Age 63)Senior Vice President of Business & Corporate Development Dr. Philippe Busque Ph.D.Senior Vice President of Global Sales & ServicesMs. Connie WedelChief People OfficerMr. Melik UlusuSenior Vice President of Operations & Integrated Supply ChainMore ExecutivesKey CompetitorsQuanterixNASDAQ:QTRXValnevaNASDAQ:VALNEyePoint PharmaceuticalsNASDAQ:EYPTMyriad GeneticsNASDAQ:MYGNAllogene TherapeuticsNASDAQ:ALLOView All CompetitorsInsiders & InstitutionsCitigroup Inc.Sold 31,805 shares on 12/6/2023Ownership: 0.028%Wellington Management Group LLPBought 99,170 shares on 12/1/2023Ownership: 1.066%Patrik JeanmonodSold 3,000 sharesTotal: $20,820.00 ($6.94/share)Deutsche Bank AGBought 15,811 shares on 11/24/2023Ownership: 0.049%Public Sector Pension Investment BoardSold 19,058 shares on 11/22/2023Ownership: 0.091%View All Insider TransactionsView All Institutional Transactions CTKB Stock Analysis - Frequently Asked Questions Should I buy or sell Cytek Biosciences stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytek Biosciences in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CTKB shares. View CTKB analyst ratings or view top-rated stocks. What is Cytek Biosciences' stock price target for 2024? 4 equities research analysts have issued 1 year target prices for Cytek Biosciences' stock. Their CTKB share price targets range from $7.00 to $14.00. On average, they anticipate the company's share price to reach $10.33 in the next year. This suggests a possible upside of 34.9% from the stock's current price. View analysts price targets for CTKB or view top-rated stocks among Wall Street analysts. How have CTKB shares performed in 2023? Cytek Biosciences' stock was trading at $10.21 on January 1st, 2023. Since then, CTKB shares have decreased by 25.0% and is now trading at $7.66. View the best growth stocks for 2023 here. Are investors shorting Cytek Biosciences? Cytek Biosciences saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 8,380,000 shares, an increase of 5.8% from the October 31st total of 7,920,000 shares. Based on an average daily trading volume, of 1,070,000 shares, the short-interest ratio is currently 7.8 days. Currently, 7.2% of the company's stock are sold short. View Cytek Biosciences' Short Interest. When is Cytek Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024. View our CTKB earnings forecast. How were Cytek Biosciences' earnings last quarter? Cytek Biosciences, Inc. (NASDAQ:CTKB) issued its quarterly earnings results on Tuesday, November, 7th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by $0.02. The company had revenue of $48 million for the quarter, compared to analysts' expectations of $55.09 million. Cytek Biosciences had a negative trailing twelve-month return on equity of 1.73% and a negative net margin of 7.61%. What ETF holds Cytek Biosciences' stock ? First Trust Nasdaq Lux Digital Health Solutions ETF holds 446 shares of CTKB stock, representing 0.46% of its portfolio. When did Cytek Biosciences IPO? (CTKB) raised $248 million in an initial public offering (IPO) on Friday, July 23rd 2021. The company issued 14,564,635 shares at a price of $16.00-$18.00 per share. Who are Cytek Biosciences' major shareholders? Cytek Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include RA Capital Management L.P. (4.99%), New York State Common Retirement Fund (1.72%), Wellington Management Group LLP (1.07%), Northern Trust Corp (0.84%), Charles Schwab Investment Management Inc. (0.61%) and Bank of New York Mellon Corp (0.61%). Insiders that own company stock include Jack Ball, Ming Yan, Patrik Jeanmonod, Ra Capital Management, LP and Wenbin Jiang. View institutional ownership trends. How do I buy shares of Cytek Biosciences? Shares of CTKB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:CTKB) was last updated on 12/11/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytek Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.